NCT05333107 - A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

July 22, 2022

Study Completion Date

September 23, 2022

Conditions

Healthy Volunteers; High Cholesterol

Interventions

DRUG

NNC0385-0434 G

Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

DRUG

NNC0385-0434 F

Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

DRUG

NNC0385-0434 B

Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).

Trial Locations (2)

90630

Altasciences, Cypress

Altasciences Clinical Los Angeles, Inc., Los Angeles